Brief

Pfizer's $50M EpiPen Deal Gets Final OK In Antitrust Suit

By Nadia Dreid · July 11, 2024, 8:43 PM EDT

Pfizer is officially out of a lawsuit accusing it of working with Mylan Pharmaceuticals to inflate the price of the popular auto-injecting emergency allergy medication EpiPen after a Kansas federal judge...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Recent Articles By Nadia

June 27, 2024
Judge OKs $10M Deal In Generic Price-Fixing MDL
April 16, 2024
NC Treasurer Backs FTC On Hospital Merger Challenge
April 09, 2024
White House, Senate Dems Want $1.3B To Fight COVID Fraud
March 01, 2024
NY Judge Tosses $6.4B BMS Investor Action For Good
February 21, 2024
39 AGs Call For Federal Pharmacy Benefit Manager Reform
February 05, 2024
States Ask Justices To End Feds' Alleged Online Censorship
January 10, 2024
Union Funds Exit Amgen, Teva Antitrust MDL
December 07, 2023
Ariz. BCBS Rips 'Kitchen-Sink' Suit Over Low Doctor Payouts
November 20, 2023
Invisalign Antitrust Classes Win Some, Lose Some On Cert.
September 22, 2023
11th Circ. Not Convinced $2.67B Blue Cross Deal Was Bad